Toronto Dominion Bank
KPTI icon

Toronto Dominion Bank’s Karyopharm Therapeutics KPTI Stock Holding History

Toronto Dominion Bank’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-113
Closed -$17K – 1268
2016
Q3 		$17K Buy
+113
New +$13.6K ﹤0.01% 1116

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Toronto Dominion Bank's KPTI Position: Q4 2016 in Review

Toronto Dominion Bank sold out of Karyopharm Therapeutics (KPTI) in Q4 2016, closing a stake of 113 shares — an estimated $17K sold.

Toronto Dominion Bank first reported a position in KPTI in Q3 2016 and held it in 1 quarter. The position peaked at $17K in Q3 2016. 86 funds tracked by Wall St. Rank hold KPTI as of Q4 2016.

  • Toronto Dominion Bank reported no remaining Karyopharm Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Toronto Dominion Bank sold 113 Karyopharm Therapeutics shares in Q4 2016, an estimated $17K.
  • Toronto Dominion Bank first reported a position in Karyopharm Therapeutics in Q3 2016 and held it in 1 quarter.
  • Toronto Dominion Bank's Karyopharm Therapeutics position peaked at $17K in Q3 2016.
  • 86 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2016.

Based on Toronto Dominion Bank's 13F filing for Q4 2016, filed 6 Feb 2017.